AIGH Capital Management LLC Sells 2,611,515 Shares of Beyond Air, Inc. (NASDAQ:XAIR)

Posted by Tyrone Williams on Mar 30th, 2025

AIGH Capital Management LLC reduced its stake in Beyond Air, Inc. (NASDAQ:XAIR – Free Report) by 72.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 991,476 shares of the company’s stock after selling 2,611,515 shares during the quarter. AIGH Capital Management LLC owned approximately 1.30% of Beyond Air worth $355,000 at the end of the most recent quarter.

Separately, Soros Fund Management LLC bought a new position in Beyond Air in the 3rd quarter worth approximately $573,000. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Insider Buying and Selling at Beyond Air

In other news, Director Robert Carey bought 1,000,000 shares of the stock in a transaction dated Friday, March 14th. The stock was purchased at an average price of $0.25 per share, for a total transaction of $250,000.00. Following the acquisition, the director now owns 4,076,864 shares of the company’s stock, valued at $1,019,216. The trade was a 32.50 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 20.10% of the company’s stock.

Beyond Air Price Performance

NASDAQ XAIR opened at $0.27 on Friday. The stock has a market capitalization of $18.72 million, a PE ratio of -0.26 and a beta of 0.16. Beyond Air, Inc. has a 1-year low of $0.24 and a 1-year high of $1.75. The business has a 50 day simple moving average of $0.33 and a two-hundred day simple moving average of $0.40.

Beyond Air (NASDAQ:XAIR – Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. Beyond Air had a negative net margin of 1,730.00% and a negative return on equity of 226.01%. During the same period in the previous year, the firm earned ($0.50) EPS. On average, analysts anticipate that Beyond Air, Inc. will post -0.79 EPS for the current fiscal year.

About Beyond Air

(Free Report)

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.